James Pineno, MD
Family Medicine · Venice, FLNPI 1578862447
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,776 of the $4,976 with a category attached, or 75.9%. 26 manufacturers reported payments, led by Biohaven Pharmaceuticals, Inc. at 24.6% of the total. Reporting peaked in 2021 at $1,734 and has fallen 98.8% since, to $21 in 2025. Among family medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- Novo Nordisk$792
- AbbVie$607
- Pfizer$292
- Lilly USA, LLC$268
- AstraZeneca$260
- plus $2K from 20 others
What the payments were for
- Consulting fees$1,20024%
- Food & beverage$3,77676%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 3 | $1,224 |
| Novo Nordisk | 48 | $792 |
| AbbVie(2 entities) | 34 | $607 |
| Pfizer | 18 | $292 |
| Lilly USA, LLC | 18 | $268 |
| AstraZeneca | 17 | $260 |
| Exact Sciences | 8 | $209 |
| GSK | 13 | $196 |
| Amgen(2 entities) | 11 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $167 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $134 |
| Johnson & Johnson | 9 | $116 |
| Astellas Pharma US Inc | 7 | $93 |
| Amarin Pharma, Inc. | 5 | $89 |
| Bayer | 3 | $83 |
| Merck | 4 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Novartis | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Abbott | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Neos Therapeutics, LP | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
How this compares
$4,976 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $99,630 |
| TrulicityDulaglutide | 18 | $35,040 |
| EliquisApixaban | 21 | $33,755 |
| RybelsusSemaglutide | 20 | $26,358 |
| XareltoRivaroxaban | 17 | $24,251 |
| FarxigaDapagliflozin Propanediol | 18 | $21,008 |
| Repatha SureclickEvolocumab | 15 | $18,986 |
| MounjaroTirzepatide | 12 | $18,971 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $18,652 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $14,905 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $12,854 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $7,920 |
| Atorvastatin Calcium | 311 | $2,851 |
| SynthroidLevothyroxine Sodium | 22 | $1,943 |
| Rosuvastatin Calcium | 179 | $1,873 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $792 | $125,98884 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $268 | $54,01130 claims |
| PfizerEliquis | $292 | $33,75521 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $196 | $26,57231 claims |
| Johnson & JohnsonXarelto | $116 | $24,25117 claims |
| AstraZenecaFarxiga | $260 | $21,00818 claims |
| AbbVieSynthroid | $607 | $1,94322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Venice
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.